{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:02:01Z","timestamp":1790949721942,"version":"4.1.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T00:00:00Z","timestamp":1454457600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T00:00:00Z","timestamp":1454457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:p>In patients with cirrhosis and hepatorenal syndrome (HRS), terlipressin has been used either as continuous intravenous infusion or as intravenous boluses. To date, these two approaches have never been compared. The goal of this study was to compare the administration of terlipressin as continuous intravenous infusion versus intravenous boluses in the treatment of type 1 HRS. Seventy\u2010eight patients were randomly assigned to receive either continuous intravenous infusion (TERLI\u2010INF group) at the initial dose of 2 mg\/day or intravenous boluses of terlipressin (TERLI\u2010BOL group) at the initial dose of 0.5 mg every 4 hours. In case of no response, the dose was progressively increased to a final dose of 12 mg\/day in both groups. Albumin was given at the same dose in both groups (1 g\/kg of body weight at the first day followed by 20\u201040 g\/day). Complete response was defined by decrease of serum creatinine (sCr) from baseline to a final value \u2264133 \u03bcmol\/L, partial response by a decrease \u226550% of sCr from baseline to a final value &gt;133 \u03bcmol\/L. The rate of adverse events was lower in the TERLI\u2010INF group (35.29%) than in the TERLI\u2010BOL group (62.16%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.025). The rate of response to treatment, including both complete and partial response, was not significantly different between the two groups (76.47% versus 64.85%; <jats:italic toggle=\"yes\">P<\/jats:italic> value not significant). The mean daily effective dose of terlipressin was lower in the TERLI\u2010INF group than in the TERLI\u2010BOL group (2.23 \u00b1 0.65 versus 3.51 \u00b1 1.77 mg\/day; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: Terlipressin given by continuous intravenous infusion is better tolerated than intravenous boluses in the treatment of type 1 HRS. Moreover, it is effective at doses lower than those required for intravenous bolus administration. (H<jats:sc>epatology<\/jats:sc> 2016;63:983\u2013992)<\/jats:p>","DOI":"10.1002\/hep.28396","type":"journal-article","created":{"date-parts":[[2015,12,14]],"date-time":"2015-12-14T04:38:55Z","timestamp":1450067935000},"page":"983-992","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":291,"title":["Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study"],"prefix":"10.1097","volume":"63","author":[{"given":"Marta","family":"Cavallin","sequence":"first","affiliation":[{"name":"Department of Medicine (DIMED),University of Padova,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Piano","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED),University of Padova,Italy"},{"name":"Unit of Hepatic Emergencies and Liver Transplantation,University of Padova,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Romano","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED),University of Padova,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvano","family":"Fasolato","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED),University of Padova,Italy"},{"name":"Unit of Hepatic Emergencies and Liver Transplantation,University of Padova,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Chiara","family":"Frigo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Thoracic Sciences,University of Padova,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpiero","family":"Benetti","sequence":"additional","affiliation":[{"name":"General Hospital of Melegnano,Milan,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Gola","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED),University of Padova,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Morando","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED),University of Padova,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialuisa","family":"Stanco","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED),University of Padova,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rosi","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED),University of Padova,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Sticca","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED),University of Padova,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Cillo","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Gastroenterological Sciences,Unit of Hepatobiliary Surgery and Liver Transplantation, University of Padova,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Angeli","sequence":"additional","affiliation":[{"name":"Department of Medicine (DIMED),University of Padova,Italy"},{"name":"Unit of Hepatic Emergencies and Liver Transplantation,University of Padova,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,2,3]]},"reference":[{"key":"hep28396-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","article-title":"EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis","volume":"53","year":"2010","journal-title":"J Hepatol"},{"key":"hep28396-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilatation hypotesis: a proposal for the initiation of renal sodium and water retention in cirrhosis","volume":"8","year":"1988","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"hep28396-bib-0003-20241017","first-page":"S93","article-title":"Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis","volume":"48","year":"2008","journal-title":"J Hepatol"},{"key":"hep28396-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double\u2010blind, placebo\u2010controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","year":"2008","journal-title":"Gastroenterology"},{"key":"hep28396-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","year":"2008","journal-title":"Gastroenterology"},{"key":"hep28396-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2036.2006.02706.x","article-title":"Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost","volume":"23","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"hep28396-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0168-8278(97)80428-X","article-title":"Time profile of the haemodynamic effects of terlipressin in portal hypertension","volume":"26","year":"1997","journal-title":"J Hepatol"},{"key":"hep28396-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2009.03.064","article-title":"Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration","volume":"137","year":"2009","journal-title":"Gastroenterology"},{"key":"hep28396-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep28396-bib-0010-20241017","article-title":"Hepatorenal syndrome: the last pieces of the puzzle or not yet?","year":"2015","journal-title":"Hepatology"},{"key":"hep28396-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.510230122","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club","volume":"23","year":"1996","journal-title":"Hepatology"},{"key":"hep28396-bib-0012-20241017","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"56","year":"2007","journal-title":"Gut"},{"key":"hep28396-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","article-title":"Acute\u2010on\u2010chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis","volume":"144","year":"2013","journal-title":"Gastroenterology"},{"key":"hep28396-bib-0014-20241017","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jhep.2014.06.012","article-title":"Development and validation of a prognostic score to predict mortality in patients with acute\u2010on\u2010chronic liver failure","volume":"61","year":"2014","journal-title":"J Hepatol"},{"key":"hep28396-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2174\/138945009788488396","article-title":"Terlipressin continuous infusion: please mind the solvent!","volume":"10","year":"2009","journal-title":"Curr Drug Targets"},{"key":"hep28396-bib-0016-20241017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2010.11.020","article-title":"Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics","volume":"55","year":"2011","journal-title":"J Hepatol"},{"key":"hep28396-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.23283","article-title":"Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome","volume":"51","year":"2010","journal-title":"Hepatology"},{"key":"hep28396-bib-0018-20241017","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end\u2010stage liver disease","volume":"33","year":"2001","journal-title":"Hepatology"},{"key":"hep28396-bib-0019-20241017","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1053\/j.ajkd.2011.07.017","article-title":"Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials","volume":"58","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"hep28396-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/gutjnl-2014-307526","article-title":"Acute kidney injury and acute\u2010on\u2010chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis","volume":"64","year":"2015","journal-title":"Gut"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.28396","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.28396","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201603000-00030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:35:52Z","timestamp":1729211752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201603000-00030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.28396","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,3]]},"assertion":[{"value":"2015-07-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}